Although previous studies have demonstrated the cardiovascular benefits of GLP-1 RAs [1, 3], our real-world comparison between GLP-1 RAs and DPP4is in patients with comorbid T2D and hypertension did not reveal a statistically significant difference in the primary cardiovascular outcomes. This evidence concerns the gene GLP1R and Hypertension.